Skip to main content
OpenTrials

Clinical trial condition

Lung Neoplasms

Explore clinical trials studying Lung Neoplasms. Study availability and eligibility vary by location and protocol.

4,227 public trials 1,016 recruiting studies
Refine in advanced search Browse all conditions

Lung Neoplasms trial results

Completed

A Study to Evaluate the Clinical Efficacy of JNJ-42756493 (Erdafitinib), A Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, In Asian Participants With Advanced Non-Small-Cell Lung Cancer, Urothelial Cancer, Esophageal Cancer Or Cholangiocarcinoma

NCT02699606

Conditions
Acrocephalosyndactylia, Adenocarcinoma, Bone Diseases, +33 more
Locations
  • Beijing, China
  • Harbin, China
  • Nanjing, China
  • Seoul, South Korea
View Trial Details
Completed

An Open Label Trial of Afatinib (Giotrif) in Treatment-naive (1st Line) or Chemotherapy Pre-treated Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring EGFR Mutation(s)

NCT01853826

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +7 more
Locations
  • The Prince of Wales Hospital Randwick, New South Wales, Australia
  • Sunshine Hospital AT Albans, Victoria, Australia
  • St John of God Murdoch Murdoch, Western Australia, Australia
  • Medical University of Graz State Hospital - University Hospital Graz Graz, Austria
View all 118 locations
View Trial Details
Completed

A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors

NCT04943900

Conditions
Adenocarcinoma, Advanced Solid Tumors, Bronchial Neoplasms, +21 more
Locations
  • Local Institution - 0006 Atlanta, Georgia, United States
  • Local Institution - 0005 Baltimore, Maryland, United States
  • Local Institution - 0002 Hackensack, New Jersey, United States
  • Local Institution - 0013 Cleveland, Ohio, United States
View all 19 locations
View Trial Details
Completed

M7824 Versus Pembrolizumab as a First-line (1L) Treatment in Participants With Programmed Death-ligand 1 (PD-L1) Expressing Advanced Non-small Cell Lung Cancer (NSCLC)

NCT03631706

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
Locations
  • Oncology Specialties, PC; Clearview Cancer Institute Huntsville, Alabama, United States
  • Cedars Sinai Medical Center - Inflammatory Bowel Disease Center (Clinic Los Angeles, California, United States
  • UC Irvine Medical Center Orange, California, United States
  • Kaiser Permanente - Harbor City San Diego, California, United States
View all 119 locations
View Trial Details
Completed

Study of XB002 in Subjects With Solid Tumors (JEWEL-101)

NCT04925284

Conditions
Adnexal Diseases, Breast Diseases, Breast Neoplasms, +57 more
Locations
  • Exelixis Clinical Site #48 Birmingham, Alabama, United States
  • Exelixis Clinical Site #20 Tucson, Arizona, United States
  • Exelixis Clinical Site#95 Tucson, Arizona, United States
  • Exelixis Clinical Site#58 Little Rock, Arkansas, United States
View all 95 locations
View Trial Details
Completed

Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study

NCT04676412

Conditions
Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +9 more
Locations
  • Anhui Provincial Hospital ( Site 0108) Hefei, Anhui, China
  • The First Affiliated Hospital of Anhui Medical University ( Site 0113) Hefei, Anhui, China
  • Peking Union Medical College Hospital ( Site 0105) Beijing, Beijing Municipality, China
  • Beijing Cancer Hospital ( Site 0102) Beijing, Beijing Municipality, China
View all 17 locations
View Trial Details

Related conditions